GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40699)

  • GC92004 structure
    GC92004DPTIP (hydrochloride)
    CAS: 2361799-64-4
    Purity: >95.00%

    DPTIP is an inhibitor of neutral sphingomyelinase 2 (nSMase2; IC50 = 30 nM).

  • GC92010 structure
    GC92010SJB2-043 analog (trifluoroacetate salt)
    Purity: >95.00%

    SJB2-043 analog is an inhibitor of OTUB1 and USP8 (IC50s = 0.17 and 0.28 nM, respectively) and a derivative of the USP1/UAF1 complex and SARS-CoV-2 PLPro inhibitor SJB2-043.

  • GC92012 structure
    GC92012MT-1207 (hydrochloride)
    Purity: >98.00%

    MT-1207 is an orally active and selective adrenergic α1 and 5-HT2A receptor antagonist. MT-1207 shows IC50<0.1 nM, 0.15 nM, 1.40 nM and 0.27 nM for α1A, α1B, α1D and 5-HT2A, respectively.

  • GC92014 structure
    GC92014PKN3 Inhibitor Compound 16
    CAS: 2361545-75-5
    Purity: >98.00%

    PKN3 inhibitor compound 16 is an inhibitor of serine/threonine protein kinase N3 (IC50 = 14 nM).

  • GC92015 structure
    GC92015WYneN
    CAS: 3052492-38-0
    Purity: >95.00%

    WYneN is a chemoselective probe for the detection of sulfenylated proteins in live cells.

  • GC92016 structure
    GC92016WYneO
    CAS: 1648555-11-6
    Purity: >95.00%

    WyneO is a probe for the detection of sulfenylated proteins.

  • GC92018 structure
    GC92018N,N′-Diferuloylputrescine
    CAS: 42369-86-8
    Purity: >95.00%

    N,N′-Diferuloylputrescine is a polyamine that has been found in Z. mays and has diverse biological activities.

  • GC92019 structure
    GC920191-Octadecyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt)
    Purity: >95.00%

    1-Octadecyl-2-hydroxy-sn-glycero-3-phosphate (1-Octadecyl LPA) is a LPA analog containing stearyl alcohol at the sn-1 position.

  • GC92022 structure
    GC920224-hydroxy Nonenal Glutathione-d3
    Purity: >99.00%

    4-hydroxy Nonenal Glutathione-d3 (4-HNE-GSH-d3) is intended for use as an internal standard for the quantification of 4-HNE-GSH by GC- or LC-MS.

  • GC92023 structure
    GC92023PTX80
    CAS: 2376297-69-5
    Purity: >95.00%

    PTX80 is an antagonist of p62 (IC50 = 31.18 nM for the human receptor).

  • GC92024 structure
    GC92024BPN-01
    Purity: >90.00%

    BPN-01 is a fluorescent probe for cancer cells.

  • GC92026 structure
    GC92026D-Val-Leu-Lys-pNA
    CAS: 63589-93-5
    Purity: >98.00%

    D-Val-Leu-Lys-pNA is a colorimetric substrate for plasmin.

  • GC92028 structure
    GC92028UCM-05194 (ammonium salt)
    Purity: >95.00%

    UCM-05194 is an agonist of lysophosphatidic acid receptor 1 (LPA1).

  • GC92029 structure
    GC92029N-Lithocholyl-L-Leucine
    CAS: 2095154-73-5
    Purity: >95.00%

    N-Lithocholyl-L-leucine is a bile acid conjugate composed of lithocholic acid and L-leucine.

  • GC92030 structure
    GC92030Debio 0123 (hydrochloride)
    Purity: >98.00%

    Debio 0123 is an inhibitor of the checkpoint kinase WEE1 (IC50 = 0.8 nM).

  • GC92031 structure
    GC92031GPX4 Inhibitor 17
    Purity: >98.00%

    GPX4 inhibitor 17 is a ferrocene-containing inhibitor of glutathione peroxidase 4 (GPX4) and an inducer of ferroptosis.

  • GC92033 structure
    GC92033HPG1860
    CAS: 2226133-29-3
    Purity: >98.00%

    HPG1860 is a farnesoid X receptor (FXR) agonist.

  • GC92036 structure
    GC92036MCL0020 (trifluoroacetate salt)
    Purity: >98.00%

    MCL0020 is a melanocortin receptor 4 (MC4R) antagonist.

  • GC92037 structure
    GC92037JQKD82 (hydrochloride)
    CAS: 2863676-87-1
    Purity: >98.00%

    JQKD82 is a prodrug form of KDM5-C49, an inhibitor of Jumonji AT-rich interactive domain 1A (JARID1A), also known as lysine-specific demethylase 5A (KDM5A).

  • GC92039 structure
    GC92039NO-Rosa5

    NO-Rosa5 is a photocontrollable nitric oxide (NO) donor for in cellulo and ex vivo use.

  • GC92040 structure
    GC92040SGC0946 (trifluoroacetate salt)
    Purity: >98.00%

    SGC0946 is an inhibitor of the non-SET domain-containing methyltransferase DOT1L (IC50 = 0.3 nM).

  • GC92043 structure
    GC920439(10)-Nitrooleate
    CAS: 1092676-99-7
    Purity: >95.00%

    9(10)-Nitrooleate is a mixture of the nitroalkene endogenous lipid signaling molecules 9-nitrooleate.

  • GC92044 structure
    GC92044H1L1A1B3
    CAS: 3097638-09-7
    Purity: >95.00%

    H1L1A1B3 is an ionizable cationic lipid that has been used in combination with other lipids in the formation of LNPs for the delivery of circular RNA (circRNA) in vitro and in vivo.

  • GC92048 structure
    GC92048O12-D3-I3
    Purity: >95.00%

    O12-D3-I3 is an ionizable cationic lipid (pKa = 6.39) that has been used in the generation of lipid nanoparticles (LNPs) for siRNA delivery in vitro and in vivo.